HK1252375A1 - 喹唑啉衍生物的晶體及其製備方法 - Google Patents

喹唑啉衍生物的晶體及其製備方法

Info

Publication number
HK1252375A1
HK1252375A1 HK18111671.3A HK18111671A HK1252375A1 HK 1252375 A1 HK1252375 A1 HK 1252375A1 HK 18111671 A HK18111671 A HK 18111671A HK 1252375 A1 HK1252375 A1 HK 1252375A1
Authority
HK
Hong Kong
Prior art keywords
crystals
preparation
method therefor
quinazoline derivative
quinazoline
Prior art date
Application number
HK18111671.3A
Other languages
English (en)
Inventor
舒楚天
王金遠
王振華
馮玉真
Original Assignee
山東軒竹醫藥科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 山東軒竹醫藥科技有限公司 filed Critical 山東軒竹醫藥科技有限公司
Publication of HK1252375A1 publication Critical patent/HK1252375A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK18111671.3A 2015-12-25 2018-09-11 喹唑啉衍生物的晶體及其製備方法 HK1252375A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510997569 2015-12-25
CN201510999065 2015-12-25
CN201510999109 2015-12-25

Publications (1)

Publication Number Publication Date
HK1252375A1 true HK1252375A1 (zh) 2019-05-24

Family

ID=59089149

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18111671.3A HK1252375A1 (zh) 2015-12-25 2018-09-11 喹唑啉衍生物的晶體及其製備方法

Country Status (6)

Country Link
US (1) US10689359B2 (zh)
EP (1) EP3395811B1 (zh)
JP (1) JP6674027B2 (zh)
CN (1) CN108430990B (zh)
HK (1) HK1252375A1 (zh)
WO (1) WO2017107986A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3090528A1 (en) * 2018-02-08 2019-08-15 Neupharma, Inc. Certain chemical entities, compositions, and methods
AU2019345706B2 (en) * 2018-09-27 2024-02-22 Shanghai Yingli Pharmaceutical Co., Ltd Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10031971A1 (de) * 2000-06-30 2002-01-10 Goedecke Ag Polymorphe Formen/Hydrate von N-[4-(3-Chlor-4-fluor-phenylamino)-7-(3-morpholin-4-yl-propoxy)-chinazolin-6-yl]-acrylamid Dihydrochlorid, Verfahren zu ihrer Herstellung sowie die Verwendung derselben zur Herstellung von Medikamenten mit irreversibler Tyrosinkinasehemmwirkung
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
CN102382065B (zh) * 2010-08-30 2014-05-28 山东轩竹医药科技有限公司 苯胺取代的喹唑啉衍生物
CN102382106A (zh) 2010-08-30 2012-03-21 黄振华 苯胺取代的喹唑啉衍生物
EA024026B1 (ru) * 2010-11-25 2016-08-31 Рациофарм Гмбх Новые соли и полиморфные формы афатиниба
WO2012159457A1 (zh) * 2011-05-26 2012-11-29 山东亨利医药科技有限责任公司 喹唑啉衍生物类酪氨酸激酶抑制剂及其制备方法与应用
CN103965119B (zh) * 2013-02-02 2016-07-06 通化济达医药有限公司 含有锌结合基的不可逆egfr酪氨酸激酶抑制剂
EP3395810B1 (en) * 2015-12-25 2020-02-12 Xuanzhu Pharma Co., Ltd. Crystals of quinazoline derivative and preparation method therefor

Also Published As

Publication number Publication date
EP3395811A4 (en) 2019-06-26
US10689359B2 (en) 2020-06-23
JP6674027B2 (ja) 2020-04-01
CN108430990A (zh) 2018-08-21
JP2018538348A (ja) 2018-12-27
EP3395811A1 (en) 2018-10-31
WO2017107986A1 (zh) 2017-06-29
CN108430990B (zh) 2020-08-25
US20190002434A1 (en) 2019-01-03
EP3395811B1 (en) 2020-05-13

Similar Documents

Publication Publication Date Title
HK1248231A1 (zh) 取代的喹唑啉化合物和其使用方法
ZA201703075B (en) Substituted chromanes and method of use
GB201514756D0 (en) Compound and method of use
HK1253049A1 (zh) 糖基相互作用化合物及其使用方法
HK1254055A1 (zh) 製備奧貝膽酸及其衍生物的方法
HK1256860A1 (zh) 喹唑啉衍生物的晶體及其製備方法
GB201514760D0 (en) Compounds and method of use
HK1244278B (zh) 喹唑啉衍生物的鹽及其製備方法
IL252691B (en) A method of producing crystals of a diazabicyclooctane derivative and a stable lyophilized preparation
IL254384A0 (en) Acetate salt of buprenorphine and methods of preparing buprenorphine
GB201609786D0 (en) Compounds and method of use
HK1248122A1 (zh) 抗met抗體及其使用方法
IL257223A (en) New crystalline form and acetic acid adducts of palbociclib
IL258023A (en) Systems and methods for trigger-based modification of privacy settings associated with posts
PT3327012T (pt) Formas cristalinas de bilastina e os seus métodos de preparação
EP3239149A4 (en) Crystal form i of canagliflozin and preparation method thereof
EP3448375C0 (en) BENZOYLGLYCINE DERIVATIVES AND METHODS OF PRODUCING AND USING SUCH DERIVATIVES
PL3330267T3 (pl) Sól pochodnej chinazoliny lub jej kryształ oraz sposób wytwarzania soli pochodnej chinazoliny lub jej kryształu
HK1258438A1 (zh) 2-巰基苯並噻唑的製備方法
EP3272751A4 (en) Crystal form of ipi-145 and preparation method thereof
HK1252375A1 (zh) 喹唑啉衍生物的晶體及其製備方法
HK1244807A1 (zh) 咪唑衍生物及其中間體的製備方法和晶型
HUP1500647A2 (en) Intermediate of baricitinib and process for its preparation